Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 30:15:1566146.
doi: 10.3389/fonc.2025.1566146. eCollection 2025.

Dalpiciclib plus aromatase inhibitor versus neoadjuvant chemotherapy for ER-positive, HER2-negative breast cancer

Haoqi Wang  1   2 , Guoyu Zhang  3 , Wei Gao  1 , Sainan Li  1   2 , Shan Yang  1   2 , Xi Zhang  1   2 , Jiaxing Wang  1   2 , Chunxiao Li  1 , Shan Gao  4 , Cuizhi Geng  1   2
Affiliations

Dalpiciclib plus aromatase inhibitor versus neoadjuvant chemotherapy for ER-positive, HER2-negative breast cancer

Haoqi Wang et al. Front Oncol. .

Abstract

Background: The combination of cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) has emerged as an effective alternative to neoadjuvant chemotherapy (NCT) for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 (HER2) -negative breast cancer (BC). This single-center study retrospectively evaluated the efficacy and safety of dalpiciclib combined with an aromatase inhibitor (AI) compared to NCT.

Methods: The clinicopathological data and treatment details of patients with HR+ HER2 negative BC who underwent either neoadjuvant endocrine therapy (NET) or NCT were collected from the Fourth Hospital of Hebei Medical University. The primary endpoint of the study was the Residual Cancer Burden (RCB), while secondary endpoints included breast pathological complete response (bpCR), clinical response rates (ORR), proliferation markers, and safety profiles.

Results: Between May 2022 and June 2023, a total of 36 patients were treated with dalpiciclib plus AI, while 137 patients received NCT for the final analysis. Prior to propensity score matching (PSM), the rates of RCB 0 were 0% in the NET group and 7.3% in the NCT group (p=0.205). The rates of bpCR were 2.8% for the NET group and 13.1% for the NCT group (p=0.142). The ORR was comparable between the two groups (p=0.397), as were the rates of BCS (p=0.608). Both treatment groups demonstrated significant reductions in Ki-67 levels, although the extent of reduction was similar (p=0.174). Notably, a Ki-67 level of ≤ 10% post-treatment was more prevalent in the NET group (p<0.0001). Only two patients in the NET group achieved a Preoperative Endocrine Prognostic Index (PEPI) 0 score. The incidence of grade 3-4 toxicities was significantly higher in the NCT group compared to the NET group (p<0.05). Following PSM, patients treated with dalpiciclib plus AI exhibited comparable clinical responses and a safety advantage relative to those receiving NCT.

Conclusion: This study indicates that the combination of dalpiciclib and AI elicits comparable responses and demonstrates improved safety profiles when compared to NCT in patients with HR+ HER2 negative breast tumors. Furthermore, RCB and pCR may not serve as optimal endpoints for evaluating the efficacy of CDK4/6i-based NET.

Keywords: dalpiciclib; efficiency; hormone receptor positive/human epidermal growth factor receptor 2-negative breast cancer; neoadjuvant treatment; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Propensity score scatter plot before and after the PSM matching.
Figure 2
Figure 2
Distribution histogram of standard deviation.
Figure 3
Figure 3
Validation of PSM using SMDs.
Figure 4
Figure 4
Sensitivity analyses for PSM.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Jeong H, Ki SB. Neoadjuvant endocrine therapy in ER-positive b-reast cancer: evolution, indication, and tailored treatment strategy. T-her Adv Med Oncol. (2023) 15:17588359231200457. doi: 10.1177/17588359231200457 - DOI - PMC - PubMed
    1. Martínez-Pérez C, Turnbull AK, Kay C, Dixon JM. Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breas-t cancer. Expert Rev Anticancer Ther. (2023) 23:67–86. doi: 10.1080/14737140.2023.2162043 - DOI - PubMed
    1. Martí C, Sánchez-Méndez JI. The present and future of neoadjuvant endocrine therapy for breast cancer treatment. Cancers (Basel). (2021) 13:2538. doi: 10.3390/cancers13112538 - DOI - PMC - PubMed
    1. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, et al. . Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. (2007) 110:244–54. doi: 10.1002/cncr.22789 - DOI - PubMed
    1. Alba E, Calvo L, Albanell J, de la Haba JR, Lanza AA, Chacon JI, et al. . Chemotherapy (CT) and hormono therapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. (2012) 23:3069–74. doi: 10.1093/annonc/mds132 - DOI - PubMed

LinkOut - more resources